SCHEMBL7017433

SCHEMBL7017433

CC(OCn1cnc2cc(-c3ccncc3)ccc21)[Si](C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.39
AAK1 Q2M2I8 10/20 0.38
GRK2 P25098 1/20 0.37
NTRK1 P04629 1/20 0.37
CSF1R P07333 1/20 0.37
NTRK2 Q16620 1/20 0.37
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
PLK1 P53350 2/20 0.36
PLK3 Q9H4B4 2/20 0.36
CYP2C9 P11712 1/20 0.35
BRD4 O60885 1/20 0.35
QPCT Q16769 1/20 0.35
QPCTL Q9NXS2 1/20 0.35
CYP3A4 P08684 1/20 0.35
KDR P35968 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7017087 0.90 AAK1 (0.40) AAK1GRK2PLK1PLK3BRD4
SCHEMBL7018800 0.80 MAPT (0.35) KDM4EALDH1A1LMNAHPGD
SCHEMBL7019257 0.80 MAPT (0.55) LCKKDM4EALDH1A1QPCTQPCTL
SCHEMBL7475809 0.76 TDP1 (0.53) LMNA
SCHEMBL7017505 0.75 PKM (0.53) KDM4EALDH1A1LMNAHPGDBRD4
SCHEMBL2319934 0.74 CYP11B1 (0.38) LMNABRD4KDR
SCHEMBL2358825 0.74 CYP11B1 (0.38) LMNABRD4KDR
SCHEMBL7018562 0.73 POLB (0.36) LMNABRD4QPCTQPCTL
SCHEMBL7016871 0.72 MAPT (0.41) LCKKDM4EALDH1A1BRD4QPCT
SCHEMBL2541710 0.70 POLB (0.37) LMNABRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1206265-B1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2003-11-12 EP disclosed
US-6498165-B1 PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS MERCK & CO., INC. 2002-12-24 US disclosed